FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2099395323> ?p ?o ?g. }

• W2099395323 endingPage "253" @default.
• W2099395323 startingPage "239" @default.
• W2099395323 abstract "Targeting the ubiquitin-proteasome pathway has emerged as a rational approach in the treatment of human cancer. Based on positive preclinical and clinical studies, bortezomib was subsequently approved for the clinical use as a front-line treatment for newly diagnosed multiple myeloma patients and for the treatment of relapsed/refractory multiple myeloma and mantle cell lymphoma, for which this drug has become the staple of treatment. The approval of bortezomib by the US Food and Drug Administration (FDA) represented a significant milestone as the first proteasome inhibitor to be implemented in the treatment of malignant disease. Bortezomib has shown a positive clinical benefit either alone or as a part of combination therapy to induce chemo-/radio-sensitization or overcome drug resistance. One of the major mechanisms of bortezomib associated with its anticancer activity is through upregulation of NOXA, which is a proapoptotic protein, and NOXA may interact with the anti-apoptotic proteins of Bcl-2 subfamily Bcl-XL and Bcl-2, and result in apoptotic cell death in malignant cells. Another important mechanism of bortezomib is through suppression of the NF-κB signaling pathway resulting in the down-regulation of its anti-apoptotic target genes. Although the majority of success achieved with bortezomib has been in hematological malignancies, its effect toward solid tumors has been less than encouraging. Additionally, the widespread clinical use of bortezomib continues to be hampered by the appearance of dose-limiting toxicities, drug-resistance and interference by some natural compounds. These findings could help guide physicians in refining the clinical use of bortezomib, and encourage basic scientists to generate next generation proteasome inhibitors that broaden the spectrum of efficacy and produce a more durable clinical response in cancer patients. Other desirable applications for the use of proteasome inhibitors include the development of inhibitors against specific E3 ligases, which act at an early step in the ubiquitin-proteasome pathway, and the discovery of less toxic and novel proteasome inhibitors from natural products and traditional medicines, which may provide more viable drug candidates for cancer chemoprevention and the treatment of cancer patients in the future. Keywords: The ubiquitin-proteasome pathway, proteasome inhibitors, bortezomib, chemotherapy, multiple myeloma" @default.
• W2099395323 created "2016-06-24" @default.
• W2099395323 creator A5037229561 @default.
• W2099395323 creator A5040105324 @default.
• W2099395323 creator A5051071198 @default.
• W2099395323 creator A5058399757 @default.
• W2099395323 creator A5068066333 @default.
• W2099395323 date "2011-03-01" @default.
• W2099395323 modified "2023-10-12" @default.
• W2099395323 title "Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives" @default.
• W2099395323 cites W1495816485 @default.
• W2099395323 cites W1580378285 @default.
• W2099395323 cites W1595109869 @default.
• W2099395323 cites W1596165940 @default.
• W2099395323 cites W1599096704 @default.
• W2099395323 cites W1772903887 @default.
• W2099395323 cites W1938721925 @default.
• W2099395323 cites W193931596 @default.
• W2099395323 cites W1964175291 @default.
• W2099395323 cites W1964617786 @default.
• W2099395323 cites W1965344560 @default.
• W2099395323 cites W1965790877 @default.
• W2099395323 cites W1970001436 @default.
• W2099395323 cites W1973562117 @default.
• W2099395323 cites W1976201756 @default.
• W2099395323 cites W1976449876 @default.
• W2099395323 cites W1976582166 @default.
• W2099395323 cites W1980471295 @default.
• W2099395323 cites W1981472752 @default.
• W2099395323 cites W1984998337 @default.
• W2099395323 cites W1985275612 @default.
• W2099395323 cites W1988775004 @default.
• W2099395323 cites W1989548984 @default.
• W2099395323 cites W1989684777 @default.
• W2099395323 cites W1989740966 @default.
• W2099395323 cites W1991400488 @default.
• W2099395323 cites W1991485215 @default.
• W2099395323 cites W1991930087 @default.
• W2099395323 cites W1992629857 @default.
• W2099395323 cites W1992692251 @default.
• W2099395323 cites W1995805772 @default.
• W2099395323 cites W1996461174 @default.
• W2099395323 cites W1998297722 @default.
• W2099395323 cites W1999119754 @default.
• W2099395323 cites W2001082277 @default.
• W2099395323 cites W2002064090 @default.
• W2099395323 cites W2003924932 @default.
• W2099395323 cites W2007249806 @default.
• W2099395323 cites W2009410162 @default.
• W2099395323 cites W2009888511 @default.
• W2099395323 cites W2010163650 @default.
• W2099395323 cites W2013660816 @default.
• W2099395323 cites W2014442719 @default.
• W2099395323 cites W2014842408 @default.
• W2099395323 cites W2014847481 @default.
• W2099395323 cites W2015997780 @default.
• W2099395323 cites W2016098671 @default.
• W2099395323 cites W2016742872 @default.
• W2099395323 cites W201795241 @default.
• W2099395323 cites W2018589274 @default.
• W2099395323 cites W2021242983 @default.
• W2099395323 cites W2021457628 @default.
• W2099395323 cites W2024846074 @default.
• W2099395323 cites W2024996523 @default.
• W2099395323 cites W2025253157 @default.
• W2099395323 cites W2025517637 @default.
• W2099395323 cites W2025963365 @default.
• W2099395323 cites W2026043555 @default.
• W2099395323 cites W2026158949 @default.
• W2099395323 cites W2028491514 @default.
• W2099395323 cites W2029501972 @default.
• W2099395323 cites W2031162742 @default.
• W2099395323 cites W2031909042 @default.
• W2099395323 cites W2036180531 @default.
• W2099395323 cites W2036211695 @default.
• W2099395323 cites W2036888301 @default.
• W2099395323 cites W2038753750 @default.
• W2099395323 cites W2039355568 @default.
• W2099395323 cites W2039374629 @default.
• W2099395323 cites W2043892945 @default.
• W2099395323 cites W2051670105 @default.
• W2099395323 cites W2052388202 @default.
• W2099395323 cites W2056402897 @default.
• W2099395323 cites W2056408416 @default.
• W2099395323 cites W2064451393 @default.
• W2099395323 cites W2065480848 @default.
• W2099395323 cites W2067653691 @default.
• W2099395323 cites W2071191421 @default.
• W2099395323 cites W2074674798 @default.
• W2099395323 cites W2076194625 @default.
• W2099395323 cites W2077365696 @default.
• W2099395323 cites W2077813540 @default.
• W2099395323 cites W2078113648 @default.
• W2099395323 cites W2079100773 @default.
• W2099395323 cites W2080724286 @default.
• W2099395323 cites W2083107653 @default.
• W2099395323 cites W2083308557 @default.
• W2099395323 cites W2085379506 @default.

• next